Jasper Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2022
Filed with the SEC on May 12, 2022 and accepted by EDGAR at May 12, 2022, 16:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-01-01 to 2022-03-31 | $8.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-01-01 to 2022-03-31 | −$12.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2022-01-01 to 2022-03-31 | −$2.2m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2022-01-01 to 2022-03-31 | −$14.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-03-31 | $70.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-03-31 | $73.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-03-31 | $80.5m | us-gaap:Assets |
| Current liabilities | At period end2022-03-31 | $6.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-03-31 | $12.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-03-31 | $68.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-22-025945. Last ingested by Listed: Nov 4, 2026, 08:12 ET. Listed shows no prices and gives no investment advice.